Bend, OR, United States of America

Daniel Elmont Dobry

USPTO Granted Patents = 10 


 

Average Co-Inventor Count = 5.0

ph-index = 4

Forward Citations = 144(Granted Patents)


Company Filing History:


Years Active: 2014-2019

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Daniel Elmont Dobry

Introduction

Daniel Elmont Dobry is a notable inventor based in Bend, OR (US), recognized for his significant contributions to the field of pharmaceutical compositions. With a total of 10 patents, Dobry has made strides in developing innovative processes that enhance drug delivery systems.

Latest Patents

Among his latest patents, Dobry has focused on spray drying processes for forming solid amorphous dispersions of drugs and polymers. This method is crucial for creating pharmaceutical compositions that effectively combine a solid amorphous dispersion of a drug with a polymer. Another significant patent involves pharmaceutical compositions of dextran polymer derivatives, which include active agents and various dextran polymer derivatives. These compositions can contain from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative, showcasing the versatility of dextran in pharmaceutical applications.

Career Highlights

Throughout his career, Dobry has worked with prominent companies such as Bend Research, Inc. and Dow Global Technologies LLC. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking innovations in the pharmaceutical industry.

Collaborations

Daniel Elmont Dobry has collaborated with talented individuals in his field, including Dwayne Thomas Friesen and James Mathew Mullin. These partnerships have fostered an environment of creativity and innovation, leading to the development of impactful technologies.

Conclusion

Daniel Elmont Dobry's work exemplifies the spirit of innovation in the pharmaceutical sector. His patents and collaborations reflect a commitment to advancing drug delivery systems, ultimately benefiting the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…